Role of RNA Splicing Mutations in Diffuse Large B Cell Lymphoma
Dereje Berta,Mekonnen Girma,Mulugeta Melku,Tiruneh Adane,Bisrat Birke,Aregawi Yalew
DOI: https://doi.org/10.2147/IJGM.S414106
IF: 2.145
2023-06-15
International Journal of General Medicine
Abstract:Dereje Berta, 1 Mekonnen Girma, 2 Mulugeta Melku, 1, 3 Tiruneh Adane, 1 Bisrat Birke, 1 Aregawi Yalew 1 1 Department of Hematology and Immunohematology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia; 2 Department of Quality Assurance and Laboratory Management, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia; 3 College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia Correspondence: Dereje Berta, Email Ribonucleic acid splicing is a crucial process to create a mature mRNA molecule by removing introns and ligating exons. This is a highly regulated process, but any alteration in splicing factors, splicing sites, or auxiliary components affects the final products of the gene. In diffuse large B-cell lymphoma, splicing mutations such as mutant splice sites, aberrant alternative splicing, exon skipping, and intron retention are detected. The alteration affects tumor suppression, DNA repair, cell cycle, cell differentiation, cell proliferation, and apoptosis. As a result, malignant transformation, cancer progression, and metastasis occurred in B cells at the germinal center. B-cell lymphoma 7 protein family member A (BCL7A), cluster of differentiation 79B (CD79B), myeloid differentiation primary response gene 88 (MYD88), tumor protein P53 (TP53), signal transducer and activator of transcription (STAT), serum- and glucose-regulated kinase 1 (SGK1), Pou class 2 associating factor 1 (POU2AF1), and neurogenic locus notch homolog protein 1 (NOTCH) are the most common genes affected by splicing mutations in diffuse large B cell lymphoma. Keywords: RNA-splicing, aberrant splicing, alternative splicing, diffuse large B-cell lymphoma Non-Hodgkin lymphoma is a heterogeneous group of cancers that starts during immune system differentiation. 1 Recent reports show that more than 100 different lymphoma types have been identified. 2 These lymphomas originate from cells of the immune system such as B cells, T cells, and dendritic cells. B-cell lymphomas are another type of cancer that develops from clonal expansion and subsequent B-cell invasion of immune organs. 3 The heterogeneity is derived from different stages of mature B-cell differentiation. Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy in adults that starts from the germinal center. 4,5 Genetic alterations such as chromosomal translocations, sporadic somatic mutations, and copy number alterations, deletions, and amplifications of genes have been reported in the pathogenesis of DLBCL. 5–8 In addition, missense mutations such as immune-related epigenetic modifications that affect the function oncogenes have been involved in DLBCL genesis. 9–11 Furthermore, current evidence reveals that mutations during RNA splicing play a role in DLBCL pathogenesis. Thus, the identification of mutations in RNA splicing is important for the diagnosis, treatment, and prognosis of DLBCL. 12,13 Human genes are highly complex; it contains coding sequence exons and non-coding sequence intron. Non-coding sequence should be removed from primary transcript through RNA splicing process. 14 RNA splicing is the process by which a precursor mRNA transcript is transformed into a mature mRNA. It is a crucial process to create an mRNA molecule by removing introns and subsequently ligating exons that direct the synthesis of the protein during translation. 13 The introns are removed from the transcript by cleavage at splice site (the 5′ and 3′ ends of intron). This process most commonly begins at dinucleotide GU and AG site at 5′ end and 3′ end of primary transcript, respectively (Figure 1). Figure 1 A schematic representative pre-mRNA, coding and non-coding sequence and splicing site. The RNA splicing process contains more than five small nuclear ribonucleoproteins (snRNPs) and trans and cis-splicing elements such as more than 200 proteins (at the splice acceptor, donor, and splice site), branch points (BP), splice enhancers, splice silencers, and splicing reaction catalysts. A large RNA-protein complex called the spliceosome recognizes auxiliary elements to promote the excision of introns from the nuclear pre-mRNA. 12,13 Based on their involvement, spliceosome is classified as major and minor. About 99.5% of introns are recognized and excised by major spliceosome, which is known as U2 dependent spliceosome (U1, U2, U4, U6, and U5 snRNPs). 15,16 The major splicing reaction occurs in order to recognized relatively poorly conserved sequence of pre-mRNA at the 5' an -Abstract Truncated-
medicine, general & internal